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Abstract
Objective: To explore the potential role of CpG motif-containing oligonucleotides (CpG-ODN) in modulating the
expression of FasL in HepG2 and Fas in Jurkat cells in vitro, and to examine the effect of CpG-ODN treatment on
the HepG2 cells-mediated Jurkat cell apoptosis in vitro.
Methods: The expressions of FasL in HepG2 and Fas in Jurkat cells were examined by real time PCR and flow
cytometry (FCM). HepG2 and Jurkat cells were co-cultured, and the frequency of apoptotic Jurkat cells and levels of
activated caspase-3 were determined by FCM.
Results: Treatment with CpG-ODN down-regulated the expression of FasL in HepG2 cells in a dose- and time-
dependent manner. In addition, treatment with CpG-ODN down-regulated the Fas mRNA transcription and protein
expression in Jurkat cells. Treatment of HepG2 cells or Jurkat cells with FasL-neutralizing antibody NOK-2
remarkably inhibited the HepG2-medaited Jurkat cell apoptosis. Pre-treatment of HepG2 or Jurkat cells with CpG-
ODN significantly reduced the frequency of HepG2-mediated apoptotic Jurkat cells and inhibited the activation of
caspase-3 in Jurkat cells in vitro.
Conclusions: Our data indicated that treatment with CpG-ODN inhibited the HepG2 cells-mediated Jurkat cell
apoptosis by modulating the Fas/FasL pathway. Apparently, CpG-ODN treatment may be a potential therapeutic
reagent for HCC.
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Introduction
Tumors escape immune surveillance through multiple
mechanisms. For example, tumors can produce inhibi-
tory factors, such as transforming growth factor-b
(TGF-b) and vascular endothelial growth factor (VEGF),
leading to the reduced dendritic cell activation and
impaired tumor-specific T cell immunity [1]. Tumor
cells can up-regulate some of the functional surface
molecules, including FasL, which can actively induce the
apoptosis of the Fas-expressing activated T lymphocytes,
while others can down-regulate the expression of other
molecules, such as MHC class I and Fas [2,3]. Although
the mechanisms by which tumor cells evade immune
surveillance are not well understood, the selective induc-
tion of tumor cell apoptosis has been thought to be a
valuable strategy for tumor therapy. CpG-ODN can
function as a Th-1 adjuvant [4] and is able to activate
dendritic cells [5]. Accordingly, CpG-ODN has been
used as an adjuvant for the induction of anti-tumor
immune responses [6-8].
Hepatocellular carcinoma (HCC) is one of the most
common malignant tumors worldwide, particularly in
China. Accumulating evidences have suggested that sev-
eral mechanisms contribute to the carcinogenesis of
HCC [9,10]. The relative resistance to apoptosis trigger-
ing and the strong proliferation in HCC cells have been
thought as predominant factors contributing to the
development of HCC [11]. Recently, high levels of FasL
have been found in HCC tumor cells [12]. Given that
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trigger the apoptosis of activated T cells through the
Fas/FasL pathway, escaping from immune surveillance.
However, little is known whether CpG-ODN could
modulate the expression of FasL in HCC cells and Fas
in human T cells as well as the HCC-triggered human
T cell apoptosis.
This study aimed at exploring the potential effect of
CpG-OND treatment on the HepG2-induced Jurkat cell
apoptosis. We found that treatment with CpG-ODN
down-regulated the expression of FasL in HepG2 cells
and Fas in Jurkat cells, and inhibited the HepG2-
mediated Jurkat cell apoptosis in vitro. We discussed
the implication of our findings.
Materials & methods
Reagents
The CpG-ODN-M362 [13] used in the experiment was
synthesized by Invitrogen (Invitrogen Inc, Shanghai,
China). Oligonucleotides were dissolved in TE-buffer
(pH 8.0) containing 10 mM Tris-HCl and 1 mM EDTA
at a concentration of 100 μM, which were then ali-
quoted and stored at -20°C until use. RPMI-1640 med-
ium was obtained from Invitrogen Inc. (Carlsbad, CA,
USA). Fetal bovine serum (FBS) was purchased from
GIBCO BRL (Grand Island, NY, USA). Monoclonal anti-
body against human FasL, NOK-2, was purchased from
BD Pharmingen (San Diego, CA, USA).
Cell culture
Human hepatocellular carcinoma cell line, HepG2 and
lymphoma cell line, Jurkat were maintained in our
laboratory and cultured in RPMI-1640 medium supple-
mented with 10% FBS, 100 U/mL penicillin, and 100
μg/mL streptomycin in 25 cm
2 polystyrene flasks at 37°
C in a humidified atmosphere of 5% CO2 incubator.
Routine passage was carried out every 2 or 3 days.
Flow cytometry analysis
HepG2 cells at 5 × 10
5 cells/well were treated in dupli-
cate with 10
-4 to 5 μM CpG-ODN in 10% FBS RPMI1640
in 12-well plates for 48 h to determine the optimal
dosage of CpG-ODN for modulating the FasL expression.
In addition, HepG2 cells at 5 × 10
5 cells/well were treated
in duplicate with 1 μM CpG-ODN for 0-48 h. The cells
were harvested and stained with phycoerythrin (PE) anti-
human FasL antibody and isotype control (eBioscience,
San Diego, CA, USA). The frequency of Fas-expressing
HepG2 cells were determined by flow cytometry analysis.
Approximately, 10,000 cells from each sample were ana-
lyzed by flow cytometry on a FACS Calibur instrument
(Becton Dickinson, San Jose, CA, USA).
Jurkat cells at 5 × 10
5 cells/well were treated in dupli-
cate with 1 μMC p G - O D Nf o r2 4ha n dc u l t u r e di n
medium alone as controls. The cells were harvested and
stained with PE-anti-human Fas antibody or isotype
control (eBioscience). The frequency of Fas-expressing
cells was determined by flow cytometry analysis. Data
were analyzed using CellQuest software.
HepG2 and Jurkat cells coculture
HepG2 cells at 2 × 10
6 cells/well were cultured in 10%
FBS RPMI1640 alone or treated with 1 μMC p G - O D N
or 10 μg/ml anti-FasL antibody NOK-2 in RPMI1640
for 24 h to prepare the inducers. Jurkat cells at 2 × 10
6
cells/well were cultured 10% FBS RPMI1640 alone or
treated with 1 μMC p G - O D No r1 0μg/ml anti-FasL
antibody NOK-2 in RPMI1640 for 24 h to prepare the
target cells. These cells were cultured as the untreated
H e p G 2( 2×1 0
6) and Jurkat cells (4 × 10
5)f o r2 4h
(controls); the NOK-2-treated HepG2 and untreated Jur-
kat cells; the untreated HepG2 and the NOK-2-treated
Jurkat cells; the CpG-ODN-treated HepG2 and
untreated Jurkat cells; and the untreated HepG2 and the
CpG-ODN-treated Jurkat cells, respectively. Subse-
quently, the suspended Jurkat cells were collected and
stained with FITC-Annexin V and PI. The apoptotic
Jurkat cells were determined by flow cytometry analysis.
Data were analyzed using CellQuest software.
In addition, the unmanipul a t e dJ u r k a tc e l l so rt h e
CpG-ODN-treated Jurkat cells were harvested after co-
culture with unmanipulated HepG2 or the CpG-ODN-
treated HepG2 cells. The cells were stained with PE-
anti-activated caspase-3 using the PE-conjugated active
caspase-3 apoptosis kit (BD Pharmingen), and the acti-
vation of capsase-3 was determined by flow cytometry
analysis.
qRT-PCR
Total RNA was extracted from the unmanipulated and
CpG-ODN-treated Jurkat cells using Trizol reagent,
according to the manufacturer’s instructions (Invitrogen,
Carlsbad, CA, USA), and reversely transcribed into
cDNA using oligo (dT) 12-18 and ReverTraAce-a™
(Toyobo. Co., Japan), resepctively. The relative levels of
Fas mRNA transcripts to control GAPDH were deter-
mined by quantitative real-time PCR using the SYBR
Green One-Step kit and the specific primers on a Light-
Cycler™ (Roche Diagnostics, Mannheim, Germany).
The sequences of the primers were synthesized by Invi-
trogen (Invitrogen Inc, Shanghai, China) and are pre-
sented in Table 1. The PCR reactions containing 0.4 μM
FasL primers, 2.5 μMM g C l 2,1×S Y B RG r e e nm a s t e r
mix, and 1 μL cDNA were performed in duplicate at 95°
C for 5 min for denaturation and subjected to 40 cycles
of 95°C for 15 s, 57°C for 5 s, 72°C for 10 s and then
78°C for 5 s. Data were analyzed using LightCycler ana-
lysis software. The individual PCR efficiencies were
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expressions (rER values) for Fas and FasL were calcu-
lated by the Gene Expression’sC( T )D i f f e r e n c e( G E D )
method [15].
Statistical analysis
Data were expressed as means ± S.E.M. Statistical signif-
icance was assessed using either Student’s t-test or one-
way ANOVA followed by post hoc Dunnett, SNK test. A
value of p < 0.05 was considered significantly different.
Results
CpG-ODN downregulated the expression of FasL in
HepG2 cells in a dose- and time-dependent manner
To determine the effect of CpG-ODN treatment on the
expression of FasL, HepG2 cells were treated with var-
ious doses of CpG-ODN (10
-4-5 μM) for 12 hours, and
the frequency of FasL-positive cells was determined by
flow cytometry analysis (Figure 1A). Treatment with the
CpG-ODN at 10
-3 μM significantly reduced the fre-
quency of FasL-expressing HepG2 cells, and treatment
with increased doses of the CpG-ODN further decreased
the frequency of FasL positive HepG2 cells in vitro.
Furthermore, we found that the effects of treatment
with 1 μM CpG-ODN on the expression of FasL in
HepG2 cells were time-dependent. Evidentially, treat-
ment with 1 μM CpG-ODN for 8 h reduced the fre-
quency of FasL-expressing HepG2 cells to 28% and
treatment for 24 h decreased the frequency of FasL-
expressing HepG2 cells to near 10%. Apparently, treat-
ment with CpG-ODN inhibited the expression of FasL
in HepG2 cells in a dose- and time-dependent manner.
Effect of CpG-ODN on the Fas expression in Jurkat cells
Next, we tested whether treatment with CpG-ODN
could modulate the expression of Fas in Jurkat cells. Jur-
kat cells were treated with 1 μMC p G - O D Nf o r2 4h .
The cells were harvested and the relative levels of Fas
mRNA transcripts to control GAPDH were determined
by quantitative RT-PCR (Figure 2A). Clearly, the relative
levels of Fas mRNA transcripts in the CpG-ODN-trea-
ted Jurkat cells were reduced to 65%, as compared with
that of unmanipulated controls. Furthermore, the
expression of Fas in Jurkat cells was also examined by
flow cytometry analysis. The frequency of Fas-expressing
Jurkat cells was significantly reduced from 54% ± 2% to
35% ± 1% (Figure 2B). Therefore, CpG-ODN treatment
down-regulated the Fas mRNA transcription and protein
expression in Jurkat cells in vitro.
Effect of CpG-ODN on the HepG2-mediated Jurkat cell
apoptosis
Engagement of Fas on the cell membrane by FasL can
trigger cell apoptosis. Given that CpG-ODN treatment
down-regulated the expression of FasL in HepG2 cells
and Fas in Jurkat cells, it is possible that CpG-ODN
Table 1 the sequences of primers.










Figure 1 Treatment with CpG-ODN inhibited the expression of
FasL in HepG2 cells in a dose- and time-dependent manner. (A)
Dose effect. HepG2 cells were treated with different concentrations
of CpG-ODN for 48 h. (B) Time effect. HepG2 cells were treated with
1 μM CpG-ODN for the indicated time periods. The cells were
harvested, and the frequency of FasL-positive cells was determined
by FACS analysis. Data are expressed as mean% ± SEM of each
group of the cells from four independent experiments. *p < 0.05 vs.
controls.
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apoptosis. Accordingly, we first treated HepG2 and Jur-
kat cells with 1 μM CpG-PDN or anti-FasL NOK-2 anti-
body for 24 h for the preparation of effector and target
cells, respectively. Next, we co-cultured the unmanipu-
lated HepG2 and Jurkat cells (positive controls), the
NOK-2-treated HepG2 and untreated Jurkat cells, the
untreated HepG2 and the NOK-2-treated Jurkat cells,
the CpG-ODN-treated HepG2 and untreated Jurkat
cells, and the untreated HepG2 and the CpG-ODN-trea-
ted Jurkat cells for 24, respectively. Subsequently, the
suspended Jurkat cells were collected and the frequency
of apoptotic Jurkat cells was determined by flow cyto-
metry analysis (Figure 3). First, co-culture of HepG2
cells with Jurkat cells triggered Jurkat cell apoptosis
(Figure 3A and 3F). Pre-treatment of either HepG2 or
Jurkat cells with anti-FasL antibody significantly reduced
the frequency of apoptotic Jurkat cells (Figure 3B and
3C), indicating that the FasL/Fas pathway might be
involved in the apoptosis of Jurkat cells in this experi-
mental system.
More interestingly, co-culture of the CpG-ODN-trea-
ted HepG2 cells with unmanipulated Jurkat cells or
unmanipulated HepG2 with the CpG-ODN-treated Jur-
kat cells significantly reduced the frequency of apoptotic
Jurkat cells, particularly following treatment of Jurkat
cells with CpG-ODN. These data indicated that down-
regulation of FasL and Fas expression by CpG-ODN in
either HepG2 or Jurkat cells inhibited the HepG2 cell-
mediated Jurkat cell apoptosis in vitro.
Caspase-3 activity analysis
The activation of caspase-3 is crucial for the intrinsic
and extrinsic apoptotic pathways. Accordingly, we selec-
tively examined the activity of caspase-3, a downstream
factor of the Fas-FasL pathway. As shown in Figure 4,
the levels of activated caspase-3 were significantly
reduced in the CpG-ODN-treated Jurkat cells (28.20 ±
0.18%), as compared to unmanipulated Jurkat cells
(45.15 ± 0.13%). These data suggested that the CpG-
ODN reduced HepG2-induced Jurkat cell death through
the caspase-3-dependent apoptotic pathway.
Discussion
The up-regulated expression of FasL has been found in
various types of tumors, including melanoma, lym-
phoma, gastric carcinoma, and breast carcinoma [16]. It
has been reported that high levels of FasL expression
are associated with the presence of tumor-infiltrating
lymphocytes (TIL), leading to high susceptibility of acti-
vated T cells in tumor tissues to apoptosis triggers due
to high levels of Fas expression by activated T cells [17].
Indeed, engagement of Fas by the FasL can promote the
formation of death-inducing signaling complex, resulting
in activated T cell apoptosis. This may partially contri-
bute to tumor cells escaping from immune surveillance
and leading to tumor progression.
D u et ot h ei m p o r t a n tr o l eo fF a si nt h et u m o rp r o -
gression and metastasis, the Fas-mediated apoptosis
might be a target for cancer therapy. Notably, the apop-
totic cascade is a sequential process of many events that
can be regulated at different stages. Several agents have
been found to directly or indirectly inhibit cellular apop-
tosis. The arsenic trioxide and tumor necrosis factor-
related apoptosis-inducing ligand receptor (TRAIL) can
modulate the intrinsic and extrinsic pathways, respec-
tively [18]. The caspase activators can regulate the com-
mon pathway, and ONY-015 can regulate modulators of
the apoptosis pathways [19]. CpG-ODN can activate the
nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-B) and activated protein 1 through the Toll-
like receptor (TLR) sigaling pathway [20], and has been
Figure 2 Treatment with CpG-ODN inhibited the expression of
Fas in Jurkat cells. Jurkat cells were treated with 1 μM CpG-ODN
for 24 h, and the cells were collected. The intracellular expression of
Fas was examined by qRT-PCR (A) and FCM (B). Data are expressed
as mean% ± SEM of each group of the cells from four separate
experiments. *p < 0.05 vs. the controls.
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response. The NF-B can regulate the expression of the
FasL gene, exhibiting both anti-apoptotic and pro-apop-
totic functions [19]. In this study, we examined the
effects of CpG-ODN treatment on the HepG2 cell-
induced Jurkat cell apoptosis. We found that CpG-ODN
inhibited the expression of FasL in HepG2 in a dose-
and time-dependent manner (Figure 1). Treatment with
CpG-ODN at 1 μM for 24 h greatly inhibited the
expression of FasL in HepG2 cells in vitro. Furthermore,
we found that treatment with CpG-ODN effectively
down-regulated the expression of Fas in human Jurkat
cells (Figure 2). Jurkat cells are derived from human T
lymphocyte leukemia cells, mimic the activated T lym-
phocyte cells, and have been widely used as experimen-
tal models to study the functions of T cells [21]. In
addition, co-culturing the unmanipulated HepG2 cells
with Jurkat cells triggered a high frequency of Jurkat
cells undergoing apoptosis, which was effectively abro-
gated by pre-treatment of either HepG2 or Jurkat cells
with anti-FasL antibody. These data indicated that
HepG2 cells induced Jurkat cell apoptosis via the Fas/
FasL pathway. More importantly, pre-treatment of
Jurkat cells or HepG2 cells with CpG-ODN efficiently
inhibited the HepG2-mediated Jurkat cell apoptosis (Fig-
ure 3) and the caspase activation in Jurkat cells (Figure
4). CpG-ODN can suppress apoptosis of macrophages
via TLR9 through PKB/Akt/FOXO pathway [22], since
macrophages and T cells play an important role in anti-
tumor immune, our study showed CpG-ODN sup-
presses apoptosis through FasL/Fas pathway, maybe
PKB/Akt/FOXO is another way in anti-apoptosis anti-
cancer therapeutic strategies of CpG-ODN.
Currently, treatment of HCC relies on surgery, con-
ventional chemotherapy, and radiation therapy at clinic.
Other therapeutic strategies, such as an antibody target-
ing the specific molecules, are currently in trials. DNA-
based drugs, such as CpG-ODN and antisense ODN,
are regarded as a new alternative therapy for the brain
tumors [23]. The regulation of the complex signaling
pathways in tumors has been a new strategy for the
rational design of anticancer strategies. Escaping from
immune surveillance and being resistant to apoptosis
triggers play an important role in the progression and
metastasis of tumors. Our results indicated that CpG-
ODN down-regulated the FasL expression in HepG2
Figure 3 Apoptosis of Jurkat cells induced by HepG2 cells. HepG2 and Jurkat cells were cultured in medium alone or treated with 1 μM
CpG-ODN or 10 μg/ml xx μg/ml anti-FasL NOK-2 antibody for 24 h. The cells were harvested and co-cultured as the unmanipulated HepG2 and
Jurkat cells (A, positive controls), the NOK-2-treated HepG2 and unmanipulated Jurkat cells (B), the unmanipulated HepG2 and NOK_2-treated
Jurkat cells (C), the CpG-ODN-treated HepG2 and unmanipulated Jurkat cells (D) or the unmanipulated HepG2 and CpG-ODN-treated Jurkat cells
(E), respectively for 24 h. The unadhered Jurkat cells were harvested and stained with FITC-Annexin V and PI, followed by flow cytometry
analysis. (F) Quantitative analysis. The frequency of apoptotic Jurkat cells was analyzed by using CellQuest software. Data are expressed as
representative FCM or mean% ± S.E.M of each group of the cells from four independent experiments. *p < 0.05 vs. the positive controls.
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cells-mediated caspase-dependent apoptosis of Jurkat
cells. Conceivably, CpG-ODN treatment may be a pro-
mising strategy for the intervention of HCC.
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